PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin.

CBIS, Cell-Based Immunization and Screening CHO, Chinese hamster ovary CLEC-2, C-type lectin-like receptor-2 DAB, 3,3'-diaminobenzidine tetrahydrochloride ELISA, enzyme-linked immunosorbent assay Horse podoplanin PBS, phosphate-buffered saline PDPN PDPN, podoplanin PMab-219 PVDF, polyvinylidene difluoride SDS, sodium dodecyl sulfate hPDPN, human podoplanin horPDPN, horse podoplanin mAb, monoclonal antibody

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 02 11 2018
revised: 08 12 2018
accepted: 27 01 2019
entrez: 16 2 2019
pubmed: 16 2 2019
medline: 16 2 2019
Statut: epublish

Résumé

Monoclonal antibodies (mAbs) against human, mouse, rat, rabbit, dog, cat, and bovine podoplanin (PDPN), a lymphatic endothelial cell marker, have been established in our previous studies. However, mAbs against horse PDPN (horPDPN), which are useful for immunohistochemical analysis, remain to be developed. In the present study, mice were immunized with horPDPN-overexpressing Chinese hamster ovary (CHO)-K1 cells (CHO/horPDPN), and hybridomas producing mAbs against horPDPN were screened using flow cytometry. One of the mAbs, PMab-219 (IgG

Identifiants

pubmed: 30766925
doi: 10.1016/j.bbrep.2019.01.009
pii: S2405-5808(18)30268-1
pii: 100616
pmc: PMC6360987
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100616

Références

Am J Pathol. 1999 Feb;154(2):385-94
pubmed: 10027397
J Biol Chem. 2003 Dec 19;278(51):51599-605
pubmed: 14522983
Oncogene. 2004 Nov 4;23(52):8552-6
pubmed: 15361850
Int J Cancer. 2005 Mar 1;113(6):899-910
pubmed: 15515019
Pathol Int. 2005 Feb;55(2):83-6
pubmed: 15693854
Tumour Biol. 2005 Jul-Aug;26(4):195-200
pubmed: 16006773
Acta Neuropathol. 2006 May;111(5):483-8
pubmed: 16596424
Acta Neuropathol. 2006 Jun;111(6):563-8
pubmed: 16718353
Gene. 2006 Aug 15;378:52-7
pubmed: 16766141
Am J Pathol. 2007 Apr;170(4):1337-47
pubmed: 17392172
J Biol Chem. 2007 Sep 7;282(36):25993-6001
pubmed: 17616532
Cancer Sci. 2008 Jan;99(1):54-61
pubmed: 17944973
Blood. 2010 Jul 29;116(4):661-70
pubmed: 20363774
Pathol Int. 2010 Mar;60(3):193-202
pubmed: 20403045
Nucl Med Biol. 2010 Oct;37(7):785-94
pubmed: 20870153
Am J Pathol. 2011 Aug;179(2):1041-9
pubmed: 21801875
Cancer Sci. 2012 Nov;103(11):1913-9
pubmed: 22816430
Acta Histochem Cytochem. 2012 Aug 30;45(4):227-37
pubmed: 23012488
Clin Exp Metastasis. 2013 Apr;30(4):441-6
pubmed: 23161183
J Immunol. 2013 Jun 15;190(12):6239-49
pubmed: 23690472
J Equine Sci. 2009;20(2):11-4
pubmed: 24833964
Sci Rep. 2014 Aug 01;4:5924
pubmed: 25080943
Structure. 2014 Dec 2;22(12):1711-1721
pubmed: 25458834
Oncotarget. 2015 Apr 20;6(11):9045-60
pubmed: 25826087
Monoclon Antib Immunodiagn Immunother. 2015 Jun;34(3):154-61
pubmed: 26090592
Monoclon Antib Immunodiagn Immunother. 2015 Dec;34(6):396-403
pubmed: 26683179
Monoclon Antib Immunodiagn Immunother. 2016 Feb;35(1):41-7
pubmed: 26788987
Monoclon Antib Immunodiagn Immunother. 2016 Jun 7;35(4):186-190
pubmed: 27267652
Monoclon Antib Immunodiagn Immunother. 2016 Aug;35(4):212-6
pubmed: 27380308
Monoclon Antib Immunodiagn Immunother. 2017 Oct;36(5):224-230
pubmed: 28737447
Monoclon Antib Immunodiagn Immunother. 2017 Oct;36(5):231-235
pubmed: 28910211
Monoclon Antib Immunodiagn Immunother. 2018 Apr;37(2):110-115
pubmed: 29608408
Biochem Biophys Rep. 2018 Apr 12;14:64-68
pubmed: 29872736
Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):224-228
pubmed: 30362928
Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):233-237
pubmed: 30362932
Am J Pathol. 1997 Oct;151(4):1141-52
pubmed: 9327748

Auteurs

Yoshikazu Furusawa (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
New Industry Creation Hatchery Center, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
ZENOAQ RESOURCE CO., LTD, 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima, 963-0196, Japan.

Shinji Yamada (S)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Shunsuke Itai (S)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Takuro Nakamura (T)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Miyuki Yanaka (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Masato Sano (M)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Hiroyuki Harada (H)

Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.

Masato Fukui (M)

ZENOAQ RESOURCE CO., LTD, 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima, 963-0196, Japan.

Mika K Kaneko (MK)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Yukinari Kato (Y)

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
New Industry Creation Hatchery Center, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Classifications MeSH